BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerability
Abstract Glioblastoma (GBM) is an incurable tumor where temozolomide (TMZ) resistance limits survival, even in MGMT-methylated patients. To improve stratification, we used NAD(P)H-FLIM to profile TMZ response in 35 patient-derived explants, integrating these data with transcriptomic and functional a...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Nature Publishing Group
2026-04-01
|
| Rangatū: | Cell Death Discovery |
| Urunga tuihono: | https://doi.org/10.1038/s41420-026-03112-z |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
